S&P 500   4,044.19 (+0.41%)
DOW   32,811.51 (+0.29%)
QQQ   315.13 (+0.77%)
AAPL   162.15 (+0.86%)
MSFT   282.98 (+0.88%)
META   206.84 (+0.73%)
GOOGL   100.61 (-0.77%)
AMZN   101.71 (+1.46%)
TSLA   196.21 (+1.20%)
NVDA   273.06 (+1.19%)
NIO   10.46 (+6.41%)
BABA   103.00 (+3.08%)
AMD   98.05 (+2.04%)
T   19.07 (+0.37%)
F   12.32 (+2.24%)
MU   62.86 (-1.07%)
CGC   1.78 (-1.66%)
GE   94.04 (-0.02%)
DIS   97.98 (+1.15%)
AMC   4.89 (-2.20%)
PFE   40.33 (+0.20%)
PYPL   74.33 (+0.20%)
NFLX   337.63 (+1.69%)
S&P 500   4,044.19 (+0.41%)
DOW   32,811.51 (+0.29%)
QQQ   315.13 (+0.77%)
AAPL   162.15 (+0.86%)
MSFT   282.98 (+0.88%)
META   206.84 (+0.73%)
GOOGL   100.61 (-0.77%)
AMZN   101.71 (+1.46%)
TSLA   196.21 (+1.20%)
NVDA   273.06 (+1.19%)
NIO   10.46 (+6.41%)
BABA   103.00 (+3.08%)
AMD   98.05 (+2.04%)
T   19.07 (+0.37%)
F   12.32 (+2.24%)
MU   62.86 (-1.07%)
CGC   1.78 (-1.66%)
GE   94.04 (-0.02%)
DIS   97.98 (+1.15%)
AMC   4.89 (-2.20%)
PFE   40.33 (+0.20%)
PYPL   74.33 (+0.20%)
NFLX   337.63 (+1.69%)
S&P 500   4,044.19 (+0.41%)
DOW   32,811.51 (+0.29%)
QQQ   315.13 (+0.77%)
AAPL   162.15 (+0.86%)
MSFT   282.98 (+0.88%)
META   206.84 (+0.73%)
GOOGL   100.61 (-0.77%)
AMZN   101.71 (+1.46%)
TSLA   196.21 (+1.20%)
NVDA   273.06 (+1.19%)
NIO   10.46 (+6.41%)
BABA   103.00 (+3.08%)
AMD   98.05 (+2.04%)
T   19.07 (+0.37%)
F   12.32 (+2.24%)
MU   62.86 (-1.07%)
CGC   1.78 (-1.66%)
GE   94.04 (-0.02%)
DIS   97.98 (+1.15%)
AMC   4.89 (-2.20%)
PFE   40.33 (+0.20%)
PYPL   74.33 (+0.20%)
NFLX   337.63 (+1.69%)
S&P 500   4,044.19 (+0.41%)
DOW   32,811.51 (+0.29%)
QQQ   315.13 (+0.77%)
AAPL   162.15 (+0.86%)
MSFT   282.98 (+0.88%)
META   206.84 (+0.73%)
GOOGL   100.61 (-0.77%)
AMZN   101.71 (+1.46%)
TSLA   196.21 (+1.20%)
NVDA   273.06 (+1.19%)
NIO   10.46 (+6.41%)
BABA   103.00 (+3.08%)
AMD   98.05 (+2.04%)
T   19.07 (+0.37%)
F   12.32 (+2.24%)
MU   62.86 (-1.07%)
CGC   1.78 (-1.66%)
GE   94.04 (-0.02%)
DIS   97.98 (+1.15%)
AMC   4.89 (-2.20%)
PFE   40.33 (+0.20%)
PYPL   74.33 (+0.20%)
NFLX   337.63 (+1.69%)
NASDAQ:NTLA

Intellia Therapeutics - NTLA Competitors

$36.25
-1.31 (-3.49%)
(As of 03/30/2023 02:28 PM ET)
Add
Compare
Today's Range
$35.88
$38.26
50-Day Range
$33.30
$44.82
52-Week Range
$32.44
$78.58
Volume
452,013 shs
Average Volume
1.16 million shs
Market Capitalization
$3.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.18

NTLA vs. NEOG, MYGN, CLDX, LNTH, HSKA, QDEL, RETA, NARI, ISEE, and CYTK

Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Neogen (NEOG), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Lantheus (LNTH), Heska (HSKA), QuidelOrtho (QDEL), Reata Pharmaceuticals (RETA), Inari Medical (NARI), IVERIC bio (ISEE), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.

Intellia Therapeutics vs.

Intellia Therapeutics (NASDAQ:NTLA) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends.

In the previous week, Intellia Therapeutics had 4 more articles in the media than Neogen. MarketBeat recorded 11 mentions for Intellia Therapeutics and 7 mentions for Neogen. Intellia Therapeutics' average media sentiment score of 0.63 beat Neogen's score of 0.30 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neogen
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neogen has a net margin of -2.57% compared to Intellia Therapeutics' net margin of -909.78%. Neogen's return on equity of 5.56% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics -909.78% -48.70% -38.57%
Neogen -2.57% 5.56% 4.26%

Intellia Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Intellia Therapeutics presently has a consensus price target of $87.18, suggesting a potential upside of 140.49%. Neogen has a consensus price target of $20.00, suggesting a potential upside of 14.88%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Neogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
0 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.83
Neogen
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Intellia Therapeutics received 74 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 70.09% of users gave Intellia Therapeutics an outperform vote while only 58.54% of users gave Neogen an outperform vote.

CompanyUnderperformOutperform
Intellia TherapeuticsOutperform Votes
403
70.09%
Underperform Votes
172
29.91%
NeogenOutperform Votes
329
58.54%
Underperform Votes
233
41.46%

85.6% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Neogen shares are held by institutional investors. 2.6% of Intellia Therapeutics shares are held by company insiders. Comparatively, 0.7% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neogen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$52.12 million61.22-$474.19 million-$6.18-5.87
Neogen$527.16 million7.14$48.31 million$0.05348.20

Summary

Intellia Therapeutics beats Neogen on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTLA vs. The Competition

MetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$3.19B$2.08B$4.35B$5.91B
Dividend YieldN/A0.85%2.40%4.51%
P/E Ratio-5.8732.90108.8912.95
Price / Sales61.22108.713,543.4356.19
Price / CashN/A32.9126.7970.12
Price / Book2.318.644.545.04
Net Income-$474.19M$24.17M$115.03M$191.35M
7 Day Performance-2.50%2.31%1.15%1.61%
1 Month Performance-9.76%-6.31%-6.84%-5.33%
1 Year Performance-49.78%-35.70%-15.37%-17.79%

Intellia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEOG
Neogen
1.1078 of 5 stars
$18.49
+1.3%
$20.00
+8.2%
-42.1%$3.95B$630.72M369.801,039Options Volume
News Coverage
MYGN
Myriad Genetics
1.7372 of 5 stars
$23.33
+2.3%
$26.20
+12.3%
-10.6%$1.89B$678.40M-16.782,600Insider Selling
CLDX
Celldex Therapeutics
1.5974 of 5 stars
$35.96
+3.4%
$66.67
+85.4%
+0.9%$1.70B$2.36M-15.05132Short Interest ↑
LNTH
Lantheus
2.81 of 5 stars
$79.32
-1.0%
$107.33
+35.3%
+40.0%$5.41B$935.06M233.29612Insider Selling
Short Interest ↓
HSKA
Heska
2.368 of 5 stars
$94.40
+1.2%
$121.75
+29.0%
-31.8%$1.03B$257.31M-48.91655
QDEL
QuidelOrtho
2.6939 of 5 stars
$87.86
+0.5%
$123.83
+40.9%
-22.5%$5.84B$3.27B7.097,000
RETA
Reata Pharmaceuticals
2.345 of 5 stars
$90.04
+2.9%
$96.89
+7.6%
+160.7%$3.31B$2.22M-10.52346Upcoming Earnings
Analyst Report
Short Interest ↓
Analyst Revision
News Coverage
NARI
Inari Medical
2.2439 of 5 stars
$60.45
-3.2%
$88.56
+46.5%
-33.2%$3.28B$383.47M-109.911,100
ISEE
IVERIC bio
1.5714 of 5 stars
$24.28
+0.0%
$27.30
+12.4%
+47.6%$3.33BN/A-15.9794Analyst Upgrade
Positive News
CYTK
Cytokinetics
2.4949 of 5 stars
$35.25
+0.8%
$57.71
+63.7%
-8.3%$3.35B$94.59M-8.29253Insider Selling
This page (NASDAQ:NTLA) was last updated on 3/30/2023 by MarketBeat.com Staff